Martin Petkov

Martin Petkov

Auto-generated profile, based on publicly available information

Martin Petkov

European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany 1

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CHCorinne Hübers
Corinne Hübers
APAshik Ahmed Abdul Pari
Ashik Ahmed Abdul Pari
DGDenise Grieshober
Denise Grieshober
MPMartin Petkov
Martin Petkov
ASAlexander Schmidt
Alexander Schmidt
MFMoritz Felcht
Moritz Felcht
Primary tumors and distant site metastases form a bidirectionally communicating system. Yet, the molecular mechanisms of this crosstalk are poorly understood. Here, we identified the proteolytically cleaved fragments of angiopoietin-like 4 (ANGPTL4) as contextually active protumorigenic and antitumorigenic contributors in this communication ecosystem. Preclinical studies in multiple tumor models revealed that the C-terminal fragment (cANGPTL4) promoted tumor growth and metastasis. In contrast, the N-terminal fragment of ANGPTL4 (nANGPTL4) inhibited metastasis and enhanced overall survival in a postsurgical metastasis model by inhibiting WNT signaling and reducing vascularity at the metastatic site. Tracing ANGPTL4 and its fragments in tumor patients detected full-length ANGPTL4 primarily in tumor tissues, whereas nANGPTL4 predominated in systemic circulation and correlated inversely with disease progression. The study highlights the spatial context of the proteolytic cleavage-dependent pro- and antitumorigenic functions of ANGPTL4 and identifies and validates nANGPTL4 as a novel biomarker of tumor progression and antimetastatic therapeutic agent.